Phathom Pharmaceuticals (PHAT) Stock Forecast, Price Target & Predictions
PHAT Stock Forecast
Phathom Pharmaceuticals stock forecast is as follows: an average price target of $25.83 (represents a 173.33% upside from PHAT’s last price of $9.45) and a rating consensus of 'Buy', based on 11 wall street analysts offering a 1-year stock forecast.
PHAT Price Target
The average price target for Phathom Pharmaceuticals (PHAT) is $25.83 based on 1-year price targets from 11 Wall Street analysts in the past 3 months, with a price target range of $35.00 to $12.00. This represents a potential 173.33% upside from PHAT's last price of $9.45.
PHAT Analyst Ratings
According to 11 Wall Street analysts, Phathom Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for PHAT stock is 0 'Strong Buy' (0.00%), 6 'Buy' (54.55%), 4 'Hold' (36.36%), 1 'Sell' (9.09%), and 0 'Strong Sell' (0.00%).
Phathom Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 08, 2024 | Paul Choi | Goldman Sachs | $12.00 | $11.75 | 2.13% | 26.98% |
| Jul 19, 2024 | Matthew Caufield | H.C. Wainwright | $28.00 | $10.95 | 155.82% | 196.30% |
| May 02, 2024 | Annabel Samimy | Stifel Nicolaus | $24.00 | $9.76 | 145.90% | 153.97% |
| Jan 05, 2024 | Joseph Stringer | Needham | $26.00 | $8.99 | 189.21% | 175.13% |
| Jan 04, 2023 | - | BMO Capital | $35.00 | $11.99 | 191.91% | 270.37% |
| Jan 04, 2023 | - | Needham | $25.00 | $11.99 | 108.51% | 164.55% |
| Nov 14, 2022 | - | BMO Capital | $38.00 | $10.65 | 256.81% | 302.12% |
| Nov 11, 2022 | - | Guggenheim | $30.00 | $10.78 | 178.29% | 217.46% |
The latest Phathom Pharmaceuticals stock forecast, released on Aug 08, 2024 by Paul Choi from Goldman Sachs, set a price target of $12.00, which represents a 2.13% increase from the stock price at the time of the forecast ($11.75), and a 26.98% increase from PHAT last price ($9.45).
Phathom Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 4 |
| Avg Price Target | - | - | $22.50 |
| Last Closing Price | $9.45 | $9.45 | $9.45 |
| Upside/Downside | -100.00% | -100.00% | 138.10% |
In the current month, the average price target of Phathom Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Phathom Pharmaceuticals's last price of $9.45. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 08, 2024 | Goldman Sachs | Neutral | Neutral | Hold |
| Jul 19, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jan 05, 2024 | Needham | Buy | Buy | Hold |
| May 11, 2023 | William Blair | - | Market Perform | Downgrade |
| May 11, 2023 | RBC Capital | - | Outperform | Upgrade |
| May 11, 2023 | BTIG | - | Sell | Downgrade |
| May 11, 2023 | Piper Sandler | - | Neutral | Downgrade |
| May 11, 2023 | JMP Securities | - | Perform | Downgrade |
| May 11, 2023 | Goldman Sachs | - | Sell | Downgrade |
| May 11, 2023 | Evercore ISI | - | Outperform | Upgrade |
Phathom Pharmaceuticals's last stock rating was published by Goldman Sachs on Aug 08, 2024. The company gave PHAT a "Neutral" rating, the same as its previous rate.
Phathom Pharmaceuticals Financial Forecast
Phathom Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $682.00K | - |
| Avg Forecast | $54.50M | $49.16M | $38.26M | $28.02M | $25.16M | $12.61M | $5.68M | $1.63M | $400.89K | $211.00K |
| High Forecast | $61.59M | $55.56M | $43.24M | $29.67M | $29.30M | $12.71M | $5.68M | $1.63M | $453.04K | $211.00K |
| Low Forecast | $45.35M | $40.91M | $31.84M | $26.00M | $21.03M | $12.51M | $5.68M | $1.63M | $333.58K | $211.00K |
| # Analysts | 1 | 1 | 1 | 3 | 4 | 2 | 1 | 1 | 3 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | 1.70% | - |
Phathom Pharmaceuticals's average Quarter revenue forecast for Mar 24 based on 1 analysts is $1.63M, with a low forecast of $1.63M, and a high forecast of $1.63M. PHAT's average Quarter revenue forecast represents a 138.95% increase compared to the company's last Quarter revenue of $682.00K (Dec 23).
Phathom Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 4 | 2 | 1 | 1 | 3 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | $52.72M | $-37.78M |
| Avg Forecast | $32.70M | $29.50M | $22.96M | $16.81M | $15.10M | $7.57M | $3.41M | $977.79K | $240.54K | $-33.88M |
| High Forecast | $36.95M | $33.34M | $25.94M | $17.80M | $17.58M | $7.62M | $3.41M | $977.89K | $271.83K | $-27.11M |
| Low Forecast | $27.21M | $24.55M | $19.10M | $15.60M | $12.62M | $7.51M | $3.41M | $977.68K | $200.15K | $-40.66M |
| Surprise % | - | - | - | - | - | - | - | - | 219.18% | 1.11% |
1 analysts predict PHAT's average Quarter EBITDA for Mar 24 to be $977.79K, with a high of $977.89K and a low of $977.68K. This is -98.15% lower than Phathom Pharmaceuticals's previous annual EBITDA (Dec 23) of $52.72M.
Phathom Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 4 | 2 | 1 | 1 | 3 | 1 |
| Net Income | - | - | - | - | - | - | - | - | $121.88M | $-43.42M |
| Avg Forecast | $-49.12M | $-60.97M | $-69.58M | $-79.92M | $-77.60M | $-94.92M | $-85.30M | $-85.35M | $-69.61M | $-36.47M |
| High Forecast | $-38.40M | $-47.66M | $-54.39M | $-70.33M | $-60.66M | $-74.20M | $-66.68M | $-66.72M | $-64.32M | $-29.18M |
| Low Forecast | $-57.42M | $-71.28M | $-81.35M | $-89.51M | $-90.73M | $-110.97M | $-99.73M | $-99.78M | $-74.91M | $-43.77M |
| Surprise % | - | - | - | - | - | - | - | - | -1.75% | 1.19% |
Phathom Pharmaceuticals's average Quarter net income forecast for Mar 24 is $-85.35M, with a range of $-99.78M to $-66.72M. PHAT's average Quarter net income forecast represents a -170.03% decrease compared to the company's last Quarter net income of $121.88M (Dec 23).
Phathom Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 4 | 2 | 1 | 1 | 3 | 1 |
| SG&A | - | - | - | - | - | - | - | - | $57.00M | $20.25M |
| Avg Forecast | $1.93B | $1.74B | $1.35B | $991.58M | $890.27M | $446.14M | $200.97M | $57.66M | $14.18M | $7.47M |
| High Forecast | $2.18B | $1.97B | $1.53B | $1.05B | $1.04B | $449.60M | $200.97M | $57.67M | $16.03M | $7.47M |
| Low Forecast | $1.60B | $1.45B | $1.13B | $920.10M | $743.94M | $442.67M | $200.96M | $57.66M | $11.80M | $7.47M |
| Surprise % | - | - | - | - | - | - | - | - | 4.02% | 2.71% |
Phathom Pharmaceuticals's average Quarter SG&A projection for Mar 24 is $57.66M, based on 1 Wall Street analysts, with a range of $57.66M to $57.67M. The forecast indicates a 1.17% rise compared to PHAT last annual SG&A of $57.00M (Dec 23).
Phathom Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 4 | 2 | 1 | 1 | 3 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | $-1.14 |
| Avg Forecast | $-0.76 | $-0.94 | $-1.08 | $-1.24 | $-1.20 | $-1.47 | $-1.32 | $-1.32 | $-1.08 | $-0.97 |
| High Forecast | $-0.59 | $-0.74 | $-0.84 | $-1.09 | $-0.94 | $-1.15 | $-1.03 | $-1.03 | $-1.00 | $-0.97 |
| Low Forecast | $-0.89 | $-1.10 | $-1.26 | $-1.39 | $-1.40 | $-1.72 | $-1.54 | $-1.54 | $-1.16 | $-0.97 |
| Surprise % | - | - | - | - | - | - | - | - | -0.00% | 1.18% |
According to 1 Wall Street analysts, Phathom Pharmaceuticals's projected average Quarter EPS for Mar 24 is $-1.32, with a low estimate of $-1.54 and a high estimate of $-1.03. This represents a -55124.17% decrease compared to PHAT previous annual EPS of - (Dec 23).
Phathom Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HEPA | Hepion Pharmaceuticals | $0.69 | $70.00 | 10044.93% | Buy |
| XFOR | X4 Pharmaceuticals | $0.37 | $3.67 | 891.89% | Buy |
| INZY | Inozyme Pharma | $2.69 | $14.67 | 445.35% | Buy |
| IMMX | Immix Biopharma | $1.68 | $7.00 | 316.67% | Buy |
| CNSP | CNS Pharmaceuticals | $0.13 | $0.50 | 284.62% | - |
| GPCR | Structure Therapeutics | $30.10 | $92.40 | 206.98% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.31 | $7.00 | 203.03% | Buy |
| DAWN | Day One Biopharmaceuticals | $13.34 | $38.80 | 190.85% | Buy |
| LYRA | Lyra Therapeutics | $0.18 | $0.50 | 177.78% | Hold |
| PHAT | Phathom Pharmaceuticals | $9.45 | $25.83 | 173.33% | Buy |
| CGEM | Cullinan Oncology | $12.22 | $31.50 | 157.77% | Buy |
| TERN | Terns Pharmaceuticals | $5.71 | $14.25 | 149.56% | Buy |
| KNSA | Kiniksa Pharmaceuticals | $21.09 | $36.33 | 72.26% | Buy |
| AMLX | Amylyx Pharmaceuticals | $5.19 | $6.67 | 28.52% | Buy |
| BPMC | Blueprint Medicines | $96.62 | $109.71 | 13.55% | Buy |
| VECT | VectivBio | $16.87 | $18.00 | 6.70% | Buy |
| KRTX | Karuna Therapeutics | $329.83 | $257.50 | -21.93% | Buy |